The burden of drug resistance tuberculosis in Ghana; results of the First National Survey
Resistance to Tuberculosis drugs has become a major threat to the control of tuberculosis (TB) globally. We conducted the first nation-wide drug resistance survey to investigate the level and pattern of resistance to first-line TB drugs among newly and previously treated sputum smear-positive TB cas...
Gespeichert in:
| Veröffentlicht in: | PloS one 2021-06, Vol.16 (6), p.e0252819-e0252819 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e0252819 |
|---|---|
| container_issue | 6 |
| container_start_page | e0252819 |
| container_title | PloS one |
| container_volume | 16 |
| creator | Sylverken, Augustina Angelina Kwarteng, Alexander Twumasi-Ankrah, Sampson Owusu, Michael Arthur, Rejoice Agyeiwaa Dumevi, Rexford Mawunyo Adu-Amoah, Louis Addofoh, Nicholas Okyere, Portia Boakye Dzata, Francisca Bonsu, Frank Adusi-Poku, Yaw Kranzer, Katharina Siroka, Andrew Gemert, Wayne van Dean, Anna Owusu-Dabo, Ellis |
| description | Resistance to Tuberculosis drugs has become a major threat to the control of tuberculosis (TB) globally. We conducted the first nation-wide drug resistance survey to investigate the level and pattern of resistance to first-line TB drugs among newly and previously treated sputum smear-positive TB cases. We also evaluated associations between potential risk factors and TB drug resistance. Using the World Health Organization (WHO) guidelines on conducting national TB surveys, we selected study participants from 33 health facilities from across the country, grouped into 29 clusters, and included them into the survey. Between April 2016 and June 2017, a total of 927 patients (859 new and 68 previously treated) were enrolled in the survey. Mycobacterium tuberculosis complex (MTBC) isolates were successfully cultured from 598 (65.5%) patient samples and underwent DST, 550 from newly diagnosed and 48 from previously treated patients. The proportion of patients who showed resistance to any of the TB drugs tested was 25.2% (95% CI; 21.8-28.9). The most frequent resistance was to Streptomycin (STR) (12.3%), followed by Isoniazid (INH) (10.4%), with Rifampicin (RIF), showing the least resistance of 2.4%. Resistance to Isoniazid and Rifampicin (multi-drug resistance) was found in 19 (3.2%; 95% CI: 1.9-4.9) isolates. Prevalence of multidrug resistance was 7 (1.3%; 95% CI: 0.5-2.6) among newly diagnosed and 12 (25.0%; 95% CI: 13.6-39.6) among previously treated patients. At both univariate and multivariate analysis, MDR-TB was positively associated with previous history of TB treatment (OR = 5.09, 95% CI: 1.75-14.75, p = 0.003); (OR = 5.41, 95% CI: 1.69-17.30, p = 0.004). The higher levels of MDR-TB and overall resistance to any TB drug among previously treated patients raises concerns about adherence to treatment. This calls for strengthening existing TB programme measures to ensure a system for adequately testing and monitoring TB drug resistance. |
| doi_str_mv | 10.1371/journal.pone.0252819 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_2539883870</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A664757176</galeid><doaj_id>oai_doaj_org_article_54c3859089d740e59861d16c32aa310a</doaj_id><sourcerecordid>A664757176</sourcerecordid><originalsourceid>FETCH-LOGICAL-c720t-dae4c4aae8a4d8258f09c01512a9ccf21e0003f4350758c19cc5629eb81e4df53</originalsourceid><addsrcrecordid>eNqNk21rFDEQxxdR7IN-A8EFQfTFnXnY7GYpCKXYelAs2Cr4KsxlZ-9y7G3OPJT225v1VulKX5i8SJj85j-TSSbLXlEyp7yiHzY2uh66-c72OCdMMEnrJ9khrTmblYzwpw_2B9mR9xtCBJdl-Tw74AVNQ9SH2Y-bNebL6Brsc9vmjYur3KE3PkCvMQ9xiU7HziZLbvr8Yg09nAxE7IIfPELyPzfOh_wLBGNTRvl1dLd4_yJ71kLn8eW4Hmffzj_dnH2eXV5dLM5OL2e6YiTMGsBCFwAooWgkE7IltSZUUAa11i2jSAjhbcEFqYTUNBlFyWpcSopF0wp-nL3e6-5SlmqsildM8FpKLiuSiMWeaCxs1M6ZLbh7ZcGo3wbrVgpcMLpDJQrNpaiJrJuqIChqWdKGlpozAE4JJK2PY7S43GKjsQ8Ouono9KQ3a7Wytyq9Dq1JmQTejQLO_ozog9oar7HroEcbh7wLIhilpUzom3_Qx283UitIFzB9a1NcPYiq07IsKlHRagg7f4RKs8Gt0ekLtSbZJw7vJw6JCXgXVhC9V4vrr__PXn2fsm8fsGuELqy97eLwd_wULPagdtZ7h-3fIlOihg74Uw01dIAaO4D_ArJz9b8</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2539883870</pqid></control><display><type>article</type><title>The burden of drug resistance tuberculosis in Ghana; results of the First National Survey</title><source>DOAJ Directory of Open Access Journals</source><source>Public Library of Science (PLoS) Journals Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><creator>Sylverken, Augustina Angelina ; Kwarteng, Alexander ; Twumasi-Ankrah, Sampson ; Owusu, Michael ; Arthur, Rejoice Agyeiwaa ; Dumevi, Rexford Mawunyo ; Adu-Amoah, Louis ; Addofoh, Nicholas ; Okyere, Portia Boakye ; Dzata, Francisca ; Bonsu, Frank ; Adusi-Poku, Yaw ; Kranzer, Katharina ; Siroka, Andrew ; Gemert, Wayne van ; Dean, Anna ; Owusu-Dabo, Ellis</creator><contributor>Quinn, Frederick</contributor><creatorcontrib>Sylverken, Augustina Angelina ; Kwarteng, Alexander ; Twumasi-Ankrah, Sampson ; Owusu, Michael ; Arthur, Rejoice Agyeiwaa ; Dumevi, Rexford Mawunyo ; Adu-Amoah, Louis ; Addofoh, Nicholas ; Okyere, Portia Boakye ; Dzata, Francisca ; Bonsu, Frank ; Adusi-Poku, Yaw ; Kranzer, Katharina ; Siroka, Andrew ; Gemert, Wayne van ; Dean, Anna ; Owusu-Dabo, Ellis ; Quinn, Frederick</creatorcontrib><description>Resistance to Tuberculosis drugs has become a major threat to the control of tuberculosis (TB) globally. We conducted the first nation-wide drug resistance survey to investigate the level and pattern of resistance to first-line TB drugs among newly and previously treated sputum smear-positive TB cases. We also evaluated associations between potential risk factors and TB drug resistance. Using the World Health Organization (WHO) guidelines on conducting national TB surveys, we selected study participants from 33 health facilities from across the country, grouped into 29 clusters, and included them into the survey. Between April 2016 and June 2017, a total of 927 patients (859 new and 68 previously treated) were enrolled in the survey. Mycobacterium tuberculosis complex (MTBC) isolates were successfully cultured from 598 (65.5%) patient samples and underwent DST, 550 from newly diagnosed and 48 from previously treated patients. The proportion of patients who showed resistance to any of the TB drugs tested was 25.2% (95% CI; 21.8-28.9). The most frequent resistance was to Streptomycin (STR) (12.3%), followed by Isoniazid (INH) (10.4%), with Rifampicin (RIF), showing the least resistance of 2.4%. Resistance to Isoniazid and Rifampicin (multi-drug resistance) was found in 19 (3.2%; 95% CI: 1.9-4.9) isolates. Prevalence of multidrug resistance was 7 (1.3%; 95% CI: 0.5-2.6) among newly diagnosed and 12 (25.0%; 95% CI: 13.6-39.6) among previously treated patients. At both univariate and multivariate analysis, MDR-TB was positively associated with previous history of TB treatment (OR = 5.09, 95% CI: 1.75-14.75, p = 0.003); (OR = 5.41, 95% CI: 1.69-17.30, p = 0.004). The higher levels of MDR-TB and overall resistance to any TB drug among previously treated patients raises concerns about adherence to treatment. This calls for strengthening existing TB programme measures to ensure a system for adequately testing and monitoring TB drug resistance.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0252819</identifier><identifier>PMID: 34111159</identifier><language>eng</language><publisher>San Francisco: Public Library of Science</publisher><subject>Biochemistry ; Biology and Life Sciences ; Biotechnology ; Clustering ; Collaboration ; Contamination ; Data analysis ; Decision making ; Drug resistance ; Drug resistance in microorganisms ; Drug therapy ; Editing ; Estimates ; Funding ; Health services ; Laboratories ; Medical diagnosis ; Medicine ; Medicine and Health Sciences ; Methodology ; Microscopy ; Patient outcomes ; People and Places ; Polls & surveys ; Public health ; Questionnaires ; Rifampin ; Sample size ; Science and technology ; Sputum ; Statistical analysis ; Statistical methods ; Surveys ; Tuberculosis ; Yaw</subject><ispartof>PloS one, 2021-06, Vol.16 (6), p.e0252819-e0252819</ispartof><rights>COPYRIGHT 2021 Public Library of Science</rights><rights>2021 Sylverken et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2021 Sylverken et al 2021 Sylverken et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c720t-dae4c4aae8a4d8258f09c01512a9ccf21e0003f4350758c19cc5629eb81e4df53</citedby><cites>FETCH-LOGICAL-c720t-dae4c4aae8a4d8258f09c01512a9ccf21e0003f4350758c19cc5629eb81e4df53</cites><orcidid>0000-0002-7135-2754 ; 0000-0002-7691-914X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8191906/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8191906/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,2102,2928,23866,27924,27925,53791,53793,79600,79601</link.rule.ids></links><search><contributor>Quinn, Frederick</contributor><creatorcontrib>Sylverken, Augustina Angelina</creatorcontrib><creatorcontrib>Kwarteng, Alexander</creatorcontrib><creatorcontrib>Twumasi-Ankrah, Sampson</creatorcontrib><creatorcontrib>Owusu, Michael</creatorcontrib><creatorcontrib>Arthur, Rejoice Agyeiwaa</creatorcontrib><creatorcontrib>Dumevi, Rexford Mawunyo</creatorcontrib><creatorcontrib>Adu-Amoah, Louis</creatorcontrib><creatorcontrib>Addofoh, Nicholas</creatorcontrib><creatorcontrib>Okyere, Portia Boakye</creatorcontrib><creatorcontrib>Dzata, Francisca</creatorcontrib><creatorcontrib>Bonsu, Frank</creatorcontrib><creatorcontrib>Adusi-Poku, Yaw</creatorcontrib><creatorcontrib>Kranzer, Katharina</creatorcontrib><creatorcontrib>Siroka, Andrew</creatorcontrib><creatorcontrib>Gemert, Wayne van</creatorcontrib><creatorcontrib>Dean, Anna</creatorcontrib><creatorcontrib>Owusu-Dabo, Ellis</creatorcontrib><title>The burden of drug resistance tuberculosis in Ghana; results of the First National Survey</title><title>PloS one</title><description>Resistance to Tuberculosis drugs has become a major threat to the control of tuberculosis (TB) globally. We conducted the first nation-wide drug resistance survey to investigate the level and pattern of resistance to first-line TB drugs among newly and previously treated sputum smear-positive TB cases. We also evaluated associations between potential risk factors and TB drug resistance. Using the World Health Organization (WHO) guidelines on conducting national TB surveys, we selected study participants from 33 health facilities from across the country, grouped into 29 clusters, and included them into the survey. Between April 2016 and June 2017, a total of 927 patients (859 new and 68 previously treated) were enrolled in the survey. Mycobacterium tuberculosis complex (MTBC) isolates were successfully cultured from 598 (65.5%) patient samples and underwent DST, 550 from newly diagnosed and 48 from previously treated patients. The proportion of patients who showed resistance to any of the TB drugs tested was 25.2% (95% CI; 21.8-28.9). The most frequent resistance was to Streptomycin (STR) (12.3%), followed by Isoniazid (INH) (10.4%), with Rifampicin (RIF), showing the least resistance of 2.4%. Resistance to Isoniazid and Rifampicin (multi-drug resistance) was found in 19 (3.2%; 95% CI: 1.9-4.9) isolates. Prevalence of multidrug resistance was 7 (1.3%; 95% CI: 0.5-2.6) among newly diagnosed and 12 (25.0%; 95% CI: 13.6-39.6) among previously treated patients. At both univariate and multivariate analysis, MDR-TB was positively associated with previous history of TB treatment (OR = 5.09, 95% CI: 1.75-14.75, p = 0.003); (OR = 5.41, 95% CI: 1.69-17.30, p = 0.004). The higher levels of MDR-TB and overall resistance to any TB drug among previously treated patients raises concerns about adherence to treatment. This calls for strengthening existing TB programme measures to ensure a system for adequately testing and monitoring TB drug resistance.</description><subject>Biochemistry</subject><subject>Biology and Life Sciences</subject><subject>Biotechnology</subject><subject>Clustering</subject><subject>Collaboration</subject><subject>Contamination</subject><subject>Data analysis</subject><subject>Decision making</subject><subject>Drug resistance</subject><subject>Drug resistance in microorganisms</subject><subject>Drug therapy</subject><subject>Editing</subject><subject>Estimates</subject><subject>Funding</subject><subject>Health services</subject><subject>Laboratories</subject><subject>Medical diagnosis</subject><subject>Medicine</subject><subject>Medicine and Health Sciences</subject><subject>Methodology</subject><subject>Microscopy</subject><subject>Patient outcomes</subject><subject>People and Places</subject><subject>Polls & surveys</subject><subject>Public health</subject><subject>Questionnaires</subject><subject>Rifampin</subject><subject>Sample size</subject><subject>Science and technology</subject><subject>Sputum</subject><subject>Statistical analysis</subject><subject>Statistical methods</subject><subject>Surveys</subject><subject>Tuberculosis</subject><subject>Yaw</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>DOA</sourceid><recordid>eNqNk21rFDEQxxdR7IN-A8EFQfTFnXnY7GYpCKXYelAs2Cr4KsxlZ-9y7G3OPJT225v1VulKX5i8SJj85j-TSSbLXlEyp7yiHzY2uh66-c72OCdMMEnrJ9khrTmblYzwpw_2B9mR9xtCBJdl-Tw74AVNQ9SH2Y-bNebL6Brsc9vmjYur3KE3PkCvMQ9xiU7HziZLbvr8Yg09nAxE7IIfPELyPzfOh_wLBGNTRvl1dLd4_yJ71kLn8eW4Hmffzj_dnH2eXV5dLM5OL2e6YiTMGsBCFwAooWgkE7IltSZUUAa11i2jSAjhbcEFqYTUNBlFyWpcSopF0wp-nL3e6-5SlmqsildM8FpKLiuSiMWeaCxs1M6ZLbh7ZcGo3wbrVgpcMLpDJQrNpaiJrJuqIChqWdKGlpozAE4JJK2PY7S43GKjsQ8Ouono9KQ3a7Wytyq9Dq1JmQTejQLO_ozog9oar7HroEcbh7wLIhilpUzom3_Qx283UitIFzB9a1NcPYiq07IsKlHRagg7f4RKs8Gt0ekLtSbZJw7vJw6JCXgXVhC9V4vrr__PXn2fsm8fsGuELqy97eLwd_wULPagdtZ7h-3fIlOihg74Uw01dIAaO4D_ArJz9b8</recordid><startdate>20210610</startdate><enddate>20210610</enddate><creator>Sylverken, Augustina Angelina</creator><creator>Kwarteng, Alexander</creator><creator>Twumasi-Ankrah, Sampson</creator><creator>Owusu, Michael</creator><creator>Arthur, Rejoice Agyeiwaa</creator><creator>Dumevi, Rexford Mawunyo</creator><creator>Adu-Amoah, Louis</creator><creator>Addofoh, Nicholas</creator><creator>Okyere, Portia Boakye</creator><creator>Dzata, Francisca</creator><creator>Bonsu, Frank</creator><creator>Adusi-Poku, Yaw</creator><creator>Kranzer, Katharina</creator><creator>Siroka, Andrew</creator><creator>Gemert, Wayne van</creator><creator>Dean, Anna</creator><creator>Owusu-Dabo, Ellis</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-7135-2754</orcidid><orcidid>https://orcid.org/0000-0002-7691-914X</orcidid></search><sort><creationdate>20210610</creationdate><title>The burden of drug resistance tuberculosis in Ghana; results of the First National Survey</title><author>Sylverken, Augustina Angelina ; Kwarteng, Alexander ; Twumasi-Ankrah, Sampson ; Owusu, Michael ; Arthur, Rejoice Agyeiwaa ; Dumevi, Rexford Mawunyo ; Adu-Amoah, Louis ; Addofoh, Nicholas ; Okyere, Portia Boakye ; Dzata, Francisca ; Bonsu, Frank ; Adusi-Poku, Yaw ; Kranzer, Katharina ; Siroka, Andrew ; Gemert, Wayne van ; Dean, Anna ; Owusu-Dabo, Ellis</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c720t-dae4c4aae8a4d8258f09c01512a9ccf21e0003f4350758c19cc5629eb81e4df53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Biochemistry</topic><topic>Biology and Life Sciences</topic><topic>Biotechnology</topic><topic>Clustering</topic><topic>Collaboration</topic><topic>Contamination</topic><topic>Data analysis</topic><topic>Decision making</topic><topic>Drug resistance</topic><topic>Drug resistance in microorganisms</topic><topic>Drug therapy</topic><topic>Editing</topic><topic>Estimates</topic><topic>Funding</topic><topic>Health services</topic><topic>Laboratories</topic><topic>Medical diagnosis</topic><topic>Medicine</topic><topic>Medicine and Health Sciences</topic><topic>Methodology</topic><topic>Microscopy</topic><topic>Patient outcomes</topic><topic>People and Places</topic><topic>Polls & surveys</topic><topic>Public health</topic><topic>Questionnaires</topic><topic>Rifampin</topic><topic>Sample size</topic><topic>Science and technology</topic><topic>Sputum</topic><topic>Statistical analysis</topic><topic>Statistical methods</topic><topic>Surveys</topic><topic>Tuberculosis</topic><topic>Yaw</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sylverken, Augustina Angelina</creatorcontrib><creatorcontrib>Kwarteng, Alexander</creatorcontrib><creatorcontrib>Twumasi-Ankrah, Sampson</creatorcontrib><creatorcontrib>Owusu, Michael</creatorcontrib><creatorcontrib>Arthur, Rejoice Agyeiwaa</creatorcontrib><creatorcontrib>Dumevi, Rexford Mawunyo</creatorcontrib><creatorcontrib>Adu-Amoah, Louis</creatorcontrib><creatorcontrib>Addofoh, Nicholas</creatorcontrib><creatorcontrib>Okyere, Portia Boakye</creatorcontrib><creatorcontrib>Dzata, Francisca</creatorcontrib><creatorcontrib>Bonsu, Frank</creatorcontrib><creatorcontrib>Adusi-Poku, Yaw</creatorcontrib><creatorcontrib>Kranzer, Katharina</creatorcontrib><creatorcontrib>Siroka, Andrew</creatorcontrib><creatorcontrib>Gemert, Wayne van</creatorcontrib><creatorcontrib>Dean, Anna</creatorcontrib><creatorcontrib>Owusu-Dabo, Ellis</creatorcontrib><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sylverken, Augustina Angelina</au><au>Kwarteng, Alexander</au><au>Twumasi-Ankrah, Sampson</au><au>Owusu, Michael</au><au>Arthur, Rejoice Agyeiwaa</au><au>Dumevi, Rexford Mawunyo</au><au>Adu-Amoah, Louis</au><au>Addofoh, Nicholas</au><au>Okyere, Portia Boakye</au><au>Dzata, Francisca</au><au>Bonsu, Frank</au><au>Adusi-Poku, Yaw</au><au>Kranzer, Katharina</au><au>Siroka, Andrew</au><au>Gemert, Wayne van</au><au>Dean, Anna</au><au>Owusu-Dabo, Ellis</au><au>Quinn, Frederick</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The burden of drug resistance tuberculosis in Ghana; results of the First National Survey</atitle><jtitle>PloS one</jtitle><date>2021-06-10</date><risdate>2021</risdate><volume>16</volume><issue>6</issue><spage>e0252819</spage><epage>e0252819</epage><pages>e0252819-e0252819</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>Resistance to Tuberculosis drugs has become a major threat to the control of tuberculosis (TB) globally. We conducted the first nation-wide drug resistance survey to investigate the level and pattern of resistance to first-line TB drugs among newly and previously treated sputum smear-positive TB cases. We also evaluated associations between potential risk factors and TB drug resistance. Using the World Health Organization (WHO) guidelines on conducting national TB surveys, we selected study participants from 33 health facilities from across the country, grouped into 29 clusters, and included them into the survey. Between April 2016 and June 2017, a total of 927 patients (859 new and 68 previously treated) were enrolled in the survey. Mycobacterium tuberculosis complex (MTBC) isolates were successfully cultured from 598 (65.5%) patient samples and underwent DST, 550 from newly diagnosed and 48 from previously treated patients. The proportion of patients who showed resistance to any of the TB drugs tested was 25.2% (95% CI; 21.8-28.9). The most frequent resistance was to Streptomycin (STR) (12.3%), followed by Isoniazid (INH) (10.4%), with Rifampicin (RIF), showing the least resistance of 2.4%. Resistance to Isoniazid and Rifampicin (multi-drug resistance) was found in 19 (3.2%; 95% CI: 1.9-4.9) isolates. Prevalence of multidrug resistance was 7 (1.3%; 95% CI: 0.5-2.6) among newly diagnosed and 12 (25.0%; 95% CI: 13.6-39.6) among previously treated patients. At both univariate and multivariate analysis, MDR-TB was positively associated with previous history of TB treatment (OR = 5.09, 95% CI: 1.75-14.75, p = 0.003); (OR = 5.41, 95% CI: 1.69-17.30, p = 0.004). The higher levels of MDR-TB and overall resistance to any TB drug among previously treated patients raises concerns about adherence to treatment. This calls for strengthening existing TB programme measures to ensure a system for adequately testing and monitoring TB drug resistance.</abstract><cop>San Francisco</cop><pub>Public Library of Science</pub><pmid>34111159</pmid><doi>10.1371/journal.pone.0252819</doi><tpages>e0252819</tpages><orcidid>https://orcid.org/0000-0002-7135-2754</orcidid><orcidid>https://orcid.org/0000-0002-7691-914X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2021-06, Vol.16 (6), p.e0252819-e0252819 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_plos_journals_2539883870 |
| source | DOAJ Directory of Open Access Journals; Public Library of Science (PLoS) Journals Open Access; EZB-FREE-00999 freely available EZB journals; PubMed Central; Free Full-Text Journals in Chemistry |
| subjects | Biochemistry Biology and Life Sciences Biotechnology Clustering Collaboration Contamination Data analysis Decision making Drug resistance Drug resistance in microorganisms Drug therapy Editing Estimates Funding Health services Laboratories Medical diagnosis Medicine Medicine and Health Sciences Methodology Microscopy Patient outcomes People and Places Polls & surveys Public health Questionnaires Rifampin Sample size Science and technology Sputum Statistical analysis Statistical methods Surveys Tuberculosis Yaw |
| title | The burden of drug resistance tuberculosis in Ghana; results of the First National Survey |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T12%3A43%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20burden%20of%20drug%20resistance%20tuberculosis%20in%20Ghana;%20results%20of%20the%20First%20National%20Survey&rft.jtitle=PloS%20one&rft.au=Sylverken,%20Augustina%20Angelina&rft.date=2021-06-10&rft.volume=16&rft.issue=6&rft.spage=e0252819&rft.epage=e0252819&rft.pages=e0252819-e0252819&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0252819&rft_dat=%3Cgale_plos_%3EA664757176%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2539883870&rft_id=info:pmid/34111159&rft_galeid=A664757176&rft_doaj_id=oai_doaj_org_article_54c3859089d740e59861d16c32aa310a&rfr_iscdi=true |